Login to Your Account



Israeli gene therapy firm Vascular Biogenics filed for $75M IPO

By Jennifer Boggs
Managing Editor

Tuesday, June 10, 2014
Vascular Biogenics Ltd. (VBL), a 2000 start-up developing drugs for cancer and inflammatory diseases, added its name to the initial public offering (IPO) queue, filing an F-1, as an emerging growth company, to raise a proposed $75 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription